Novo Nordisk

News

Novo Nordisk gets NICE okay for obesity drug Wegovy

Novo Nordisk's new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-ap

News

Novo Nordisk moves to strengthen obesity efforts

After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics.

News

China's insulin plans will hit 2022 revenues, says Novo Nord...

Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues next year.

R&D

Novo Nordisk on seeking partnerships to expand its portfolio

Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’

News

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeove...

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 bill

News

Novo Nordisk nears EU approval of obesity drug Wegovy

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA's human medicines co

Novo Nordisk gets NICE okay for obesity drug Wegovy

Novo Nordisk moves to strengthen obesity efforts

China's insulin plans will hit 2022 revenues, says Novo Nord...

Novo Nordisk on seeking partnerships to expand its portfolio

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeove...

Novo Nordisk nears EU approval of obesity drug Wegovy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks